RLM.L Regulatory News (RLM)

24 Sep 2007 07:03

PuriCore Plc24 September 2007 Additional Studies Further Demonstrate Safety and Efficacy of PuriCore's Vashe(TM) Wound Therapy System More than 2,000 patients successfully treated including five with necrotizing fasciitis MALVERN, PENNSYLVANIA, AND STAFFORD, UK, September 24, 2007-PuriCore (LSE:PURI), the life sciences company focused on the control of infectious pathogenswith its novel, safe antimicrobial technology, today announced new clinicalresults from successful case studies showing the safety and efficacy of itsFDA-cleared Vashe Wound Therapy Solution in a variety of clinical applications.To date, nine physicians at 13 US clinical sites have used Vashe successfully totreat more than 2,000 patients with a diverse range of chronic and acute woundswith no report of adverse effects. The Vashe System produces hypochlorous acidat near-neutral pH, the same antimicrobial solution produced by the human bodyto fight infection. The clinicians reported positive results and efficacy of Vashe for the treatmentof a variety of challenging wounds including chronic venous ulcers; non-healingsurgical wounds; and necrotizing fasciitis, a rare, life-threatening bacterialinfection of the skin, subcutaneous tissue, and superficial facia with amortality rate of 20 to 60%. Five patients suffering from necrotizing fasciitiswere successfully treated with the Vashe Solution. These and other positive clinical results were presented at the NewCardiovascular Horizons and Management of the Diabetic Foot & Wound HealingConference in New Orleans, LA, September 5-8, and will be presented this week atGeorgetown University Hospital's Diabetic Limb Salvage Conference in Washington,DC. Previously, studies conducted on patients with chronic venous ulcers at theUniversity of Oxford in England that were published in the Journal of Wound Careshowed a positive and observable improvement in healing rates and pain reductionwith the use of the Vashe Solution. "We are very pleased with these promising early clinical results for the VasheSolution showing its safety and potential therapeutic value in the management ofsuch a wide variety of chronic and acute wounds," said Greg Bosch, CEO ofPuriCore. To date, all clinicians were un-paid, and these studies being conducted areinvestigator-driven and non-controlled. PuriCore plans to continue clinical workto demonstrate the efficacy of Vashe in a broad range of applications, includinginitiation of a randomized pilot study focused on post-operative burnmanagement. About Vashe The Vashe Wound Therapy System is a novel, noninvasive, easy-to-use woundtreatment process that has been shown to be complementary to existing treatmentmethods. The Vashe System is an FDA-cleared medical device used for moistening,irrigating, cleaning, and debriding acute and chronic wounds including stage Ithrough IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgicalwounds, first and second degree burns, abrasions, and minor irritations of theskin. The Vashe Solution mimics the human body's own infection fighter,hypochlorous acid, to eliminate pathogens that produce harmful toxins and odorand cause significant pain-all without any tissue damage. About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercializing proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound therapy, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. Contacts:Jennifer Guinan David CorrealeSage Strategic Marketing PuriCore610-410-8111 484-321-2706Jennifer@sagestrat.com This information is provided by RNS The company news service from the London Stock Exchange